The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.
Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding
Open accessAbstract
The aim of this study was to develop a treatment protocol for 225Ac-PSMA-617 α-radiation therapy in advanced-stage, metastatic castration-resistant prostate cancer patients with prostate-specific membrane antigen (PSMA)–positive tumor phenotype. Methods: A dosimetry estimate was calculated on the basis of time–activity curves derived from serially obtained 177Lu-PSMA-617 scans extrapolated to the physical half-life of 225Ac, assuming instant decay of unstable daughter nuclides. Salvage therapies empirically conducted with 50 (n = 4), 100 (n = 4), 150 (n = 2), and 200 kBq/kg (n = 4) of 225Ac-PSMA-617 were evaluated retrospectively regarding toxicity and treatment response. Eight of 14 patients received further cycles in either 2- or 4-mo intervals with identical or deescalated activities. Results: Dosimetry estimates for 1 MBq of 225Ac-PSMA-617 assuming a relative biologic effectiveness of 5 revealed mean doses of 2.3 Sv for salivary glands, 0.7 Sv for kidneys, and 0.05 Sv for red marrow that are composed of 99.4% α, 0.5% β, and 0.1% photon radiation, respectively. In clinical application, severe xerostomia became the dose-limiting toxicity if treatment activity exceeded 100 kBq/kg per cycle. At 100 kBq/kg, the duration of prostate-specific antigen decline was less than 4 mo, but if therapy was repeated every 2 mo patients experienced additive antitumor effects. Treatment activities of 50 kBq/kg were without toxicity but induced insufficient antitumor response in these high-tumor-burden patients. Remarkable antitumor activity by means of objective radiologic response or tumor marker decline was observed in 9 of 11 evaluable patients. Conclusion: For advanced-stage patients, a treatment activity of 100 kBq/kg of 225Ac-PSMA-617 per cycle repeated every 8 wk presents a reasonable trade-off between toxicity and biochemical response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Thus, current clinical TAT research relies greatly on indirect approximation by extrapolating pre-existing 177Lu-labeled pharmaceuticals (84, 112, 113).”
From Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists (2022) · cites this paper as [84]
In the citing paper
“However, a low probability of γ-emission and overlapping Bremsstrahlung due to β-emitters in the 225Ac decay chain preclude simultaneous treatment and dosimetry measurement in a clinical setting (84).”
From Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists (2022) · cites this paper as [84]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fosså, S. D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213755 · Cited by 3,408
(1997) · PubMed · Cited by 1,541
Stabin, M. G., Sparks, R. B., & Crowe, E. A. (2005) · PubMed · Cited by 1,340
Kratochwil, C., Bruchertseifer, F., Giesel, F. L., Weis, M., Verburg, F. A., Mottaghy, F. M., Kopka, K., Apostolidis, C., Haberkorn, U., & Morgenstern, A. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.178673 · Cited by 1,187
Self-citationRahbar, K., Ahmadzadehfar, H., Kratochwil, C., Haberkorn, U., Schäfers, M. A., Essler, M., Baum, R. P., Kulkarni, H., Schmidt, M. C., Drzezga, A. E., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.183194 · Cited by 861
Self-citationKratochwil, C., Giesel, F. L., Stefanova, M., Benešová, M., Bronzel, M., Afshar-Oromieh, A., Mier, W., Eder, M., Kopka, K., & Haberkorn, U. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.171397 · Cited by 636
Self-citationBenešová, M., Schäfer, M. K.-H., Bauder‐Wüst, U., Afshar‐Oromieh, A., Kratochwil, C., Mier, W., Haberkorn, U., Kopka, K., & Eder, M. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.147413 · Cited by 621
Self-citationGiesel, F. L., Hadaschik, B. A., Cardinale, J., Radtke, J. P., Vinsensia, M., Lehnert, W., Kesch, C. V., Tolstov, Y. L., Singer, S., Grabe, N., et al. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3573-4 · Cited by 595
Self-citationSgouros, G., Roeske, J. C., McDevitt, M. R., Palm, S., Allen, B. J., Fisher, D. R., Brill, A. B., Song, H., Howell, R. W., & Akabani, G. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.058651 · Cited by 552
Tumor therapy with targeted atomic nanogenerators.
McDevitt, M. R., Ma, D., Lai, L. T., Simon, J., Borchardt, P., Frank, R. K., Wu, K., Pellegrini, V., Curcio, M. J., Miederer, M., et al. (2001) · Science · doi:10.1126/science.1064126 · Cited by 501
Cited by
Sorted by citations
Hofman, M. S., Violet, J. A., Hicks, R. J., Ferdinandus, J., Thang, S. P., Akhurst, T. J., Iravani, A., Kong, G., Kumar, A. S. R., Murphy, D. G., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30198-0 · Cited by 1,184
Sartor, O., & de Bono, J. S. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1701695 · Cited by 546
Radioactive Main Group and Rare Earth Metals for Imaging and Therapy
Kostelnik, T. I., & Orvig, C. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00294 · Cited by 504
Nuhn, P., De Bono, J. S., Fizazi, K., Freedland, S. J., Grilli, M., Kantoff, P. W., Sonpavde, G., Sternberg, C. N., Yegnasubramanian, S., & Antonarakis, E. S. (2019) · European Urology · doi:10.1016/j.eururo.2018.03.028 · Cited by 437
Kratochwil, C., Bruchertseifer, F., Rathke, H. G., Hohenfellner, M., Giesel, F. L., Haberkorn, U., & Morgenstern, A. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.203539 · Cited by 429
Self-citationAn Overview of Targeted Alpha Therapy with 225Actinium and 213Bismuth
Morgenstern, A., Apostolidis, C., Kratochwil, C., Sathekge, M. M., Królicki, L., & Bruchertseifer, F. (2018) · Current Radiopharmaceuticals · doi:10.2174/1874471011666180502104524 · Cited by 382
Self-citation225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study
Sathekge, M. M., Bruchertseifer, F., Knoesen, O., Reyneke, F., Lawal, I. O., Lengana, T., Davis, C., Mahapane, J., Corbett, C., Vorster, M., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4167-0 · Cited by 361
Self-citationWatabe, T., Liu, Y., Kaneda‐Nakashima, K., Shirakami, Y., Lindner, T., Ooe, K., Toyoshima, A., Nagata, K., Shimosegawa, E., Haberkorn, U., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.233122 · Cited by 314
Self-citationFeuerecker, B., Tauber, R., Knorr, K., Heck, M. M., Beheshti, A., Seidl, C., Bruchertseifer, F., Pickhard, A., Gafita, A., Kratochwil, C., et al. (2020) · European Urology · doi:10.1016/j.eururo.2020.11.013 · Cited by 283
Self-citationGleisner, K. S., Chouin, N., Gabiña, P. M., Cicone, F., Gnesin, S., Stokke, C., Konijnenberg, M., Cremonesi, M., Verburg, F. A., Bernhardt, P., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05727-7 · Cited by 284
Targeted Alpha Therapy, an Emerging Class of Cancer Agents
Targeted Alpha Therapy Working Group, Parker, C. C., Lewington, V. J., Shore, N. D., Kratochwil, C., Levy, M. Y., Lindén, O., Noordzij, W., Park, J. H., & Fred Saad, C. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.4044 · Cited by 254
Self-citationTerbium-161 for PSMA-targeted radionuclide therapy of prostate cancer
Müller, C., Umbricht, C. A., Gracheva, N., Tschan, V. J., Pellegrini, G., Bernhardt, P., Zeevaart, J. R., Köster, U., Schibli, R., & van der Meulen, N. P. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04345-0 · Cited by 243
Ballal, S., Yadav, M. P., Bal, C., Sahoo, R. K., & Tripathi, M. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04567-2 · Cited by 215
Sathekge, M. M., Lawal, I. O., Bal, C., Bruchertseifer, F., Ballal, S., Cardaci, G., Davis, C., Eiber, M., Hekimsoy, T., Knoesen, O., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00638-1 · Cited by 210
Self-citation177Lu-PSMA Radioligand Therapy for Prostate Cancer
Fendler, W. P., Rahbar, K., Herrmann, K., Kratochwil, C., & Eiber, M. J. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.191023 · Cited by 206
Self-citationLiu, Y., Watabe, T., Kaneda‐Nakashima, K., Shirakami, Y., Naka, S., Ooe, K., Toyoshima, A., Nagata, K., Haberkorn, U., Kratochwil, C., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05554-2 · Cited by 197
Self-citationFirst Clinical Results for PSMA-Targeted α-Therapy Using 225Ac-PSMA-I&T in Advanced-mCRPC Patients
Zacherl, M. J., Gildehaus, F. J., Mittlmeier, L. M., Böning, G., Gosewisch, A., Wenter, V., Unterrainer, M., Schmidt-Hegemann, N.-S., Belka, C., Kretschmer, A., et al. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.251017 · Cited by 192
[68Ga]Ga-PSMA-11: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer
Hennrich, U., & Eder, M. (2021) · Pharmaceuticals · doi:10.3390/ph14080713 · Cited by 189
PSMA-Targeted Radiopharmaceuticals for Imaging and Therapy
Wester, H., & Schottelius, M. (2019) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2019.02.008 · Cited by 171
Assadi, M., Rekabpour, S. J., Jafari, E., Divband, G., Nikkholgh, B., Amini, H., Kamali, H., Ebrahimi, S., Shakibazad, N., Jokar, N., et al. (2021) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000003810 · Cited by 168
Yadav, M. P., Ballal, S., Sahoo, R. K., Tripathi, M., Seth, A., & Bal, C. (2020) · Theranostics · doi:10.7150/thno.48107 · Cited by 161
Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer
Bakht, M. K., & Beltran, H. (2025) · Nature Reviews Urology · doi:10.1038/s41585-024-00900-z · Cited by 158
Development of targeted alpha particle therapy for solid tumors.
Tafreshi, N. K., Doligalski, M. L., Tichacek, C. J., Pandya, D. N., Budzevich, M. M., El-Haddad, G., Khushalani, N. I., Moros, E. G., McLaughlin, M. L., Wadas, T. J., et al. (2019) · Molecules · doi:10.3390/molecules24234314 · Cited by 157
Current status of theranostics in prostate cancer
Virgolini, I. J., Decristoforo, C., Haug, A. R., Fanti, S., & Uprimny, C. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3882-2 · Cited by 159
Cazzamalli, S., Corso, A. D., Widmayer, F., & Neri, D. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.7b13361 · Cited by 153
Supply and clinical application of Actinium-225 and Bismuth-213.
Morgenstern, A., Apostolidis, C., & Bruchertseifer, F. (2020) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2020.02.003 · Cited by 141
Self-citationTargeted alpha therapy of mCRPC: Dosimetry estimate of 213Bismuth-PSMA-617
Kratochwil, C., Schmidt, K. F., Afshar‐Oromieh, A., Bruchertseifer, F., Rathke, H. G., Morgenstern, A., Haberkorn, U., & Giesel, F. L. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3817-y · Cited by 142
Self-citationActinium-225 for Targeted α Therapy: Coordination Chemistry and Current Chelation Approaches
Thiele, N. A., & Wilson, J. J. (2018) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2018.2494 · Cited by 142
225Ac-PSMA-617 for Therapy of Prostate Cancer
Kratochwil, C., Haberkorn, U., & Giesel, F. L. (2020) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2020.02.004 · Cited by 139
Self-citationReview of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer
Lenzo, N. P., Meyrick, D. P., & Turner, J. H. (2018) · Diagnostics · doi:10.3390/diagnostics8010016 · Cited by 136
Radiotheranostics in Cancer Diagnosis and Management
Jadvar, H., Chen, X. S., Cai, W., & Mahmood, U. (2018) · Radiology · doi:10.1148/radiol.2017170346 · Cited by 135
Bench to Bedside: Albumin Binders for Improved Cancer Radioligand Therapies
Lau, J., Jacobson, O., Niu, G., Lin, K., Bénard, F., & Chen, X. S. (2019) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00919 · Cited by 134
Radium-223 mechanism of action: implications for use in treatment combinations
Morris, M. J., Corey, E., Guise, T. A., Gulley, J. L., Kelly, W. K., Quinn, D. I., Scholz, A., & Sgouros, G. (2019) · Nature Reviews Urology · doi:10.1038/s41585-019-0251-x · Cited by 133
ICRU REPORT 96, Dosimetry-Guided Radiopharmaceutical Therapy
Sgouros, G., Bolch, W. E., Chiti, A., Dewaraja, Y. K., Emfietzoglou, D., Hobbs, R. F., Konijnenberg, M., Gleisner, K. S., Strigari, L., Yen, T., et al. (2021) · Journal of the ICRU · doi:10.1177/14736691211060117 · Cited by 139
Hammer, S., Hagemann, U. B., Zitzmann-Kolbe, S., Larsen, A., Ellingsen, C., Géraudie, S., Grant, D., Indrevoll, B., Smeets, R., von Ahsen, O., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2268 · Cited by 126
dos Santos, J. C., Schäfer, M. K.-H., Bauder‐Wüst, U., Lehnert, W., Leotta, K., Morgenstern, A., Kopka, K., Haberkorn, U., Mier, W., & Kratochwil, C. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4220-z · Cited by 126
Self-citationKozempel, J., Mokhodoeva, O. B., & Vlk, M. (2018) · Molecules · doi:10.3390/molecules23030581 · Cited by 126
Bismuth-213 for targeted radionuclide therapy: from atom to bedside.
Ahenkorah, S., Cassells, I., Deroose, C. M., Cardinaels, T., Burgoyne, A. R., Bormans, G., Ooms, M., & Cleeren, F. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13050599 · Cited by 120
“9 y) intermediate and handling of the radium target remains a challenge [22].”
BackgroundEvaluation of an Anti-HER2 Nanobody Labeled with 225Ac for Targeted α-Particle Therapy of Cancer
Pruszyński, M., D’Huyvetter, M., Bruchertseifer, F., Morgenstern, A., & Lahoutte, T. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00985 · Cited by 119
Self-citationKuo, H., Merkens, H., Zhang, Z., Uribe, C., Lau, J., Zhang, C., Colpo, N., Lin, K., & Bénard, F. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00720 · Cited by 116
α-Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studies—Part 2
Poty, S., Francesconi, L. C., McDevitt, M. R., Morris, M. J., & Lewis, J. S. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.204651 · Cited by 114
Castration-Resistant Prostate Cancer: Mechanisms, Targets and Treatment
Mansinho, A., Macedo, D., Fernandes, I., & Costa, L. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-99286-0_7 · Cited by 113
Safety and efficacy of targeted alpha therapy with 213Bi-DOTA-substance P in recurrent glioblastoma
Królicki, L., Bruchertseifer, F., Kunikowska, J., Koziara, H. M., Królicki, B., Jakuciński, M., Pawlak, D., Apostolidis, C., Mirzadeh, S., Rola, R., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4225-7 · Cited by 113
Self-citationTargeted Radionuclide Therapy of Prostate Cancer—From Basic Research to Clinical Perspectives
Czerwińska, M., Bilewicz, A., Kruszewski, M. K., Węgierek-Ciuk, A., & Lankoff, A. (2020) · Molecules · doi:10.3390/molecules25071743 · Cited by 109
Feasibility of CXCR4-Directed Radioligand Therapy in Advanced Diffuse Large B-Cell Lymphoma
Lapa, C., Hänscheid, H., Kircher, M., Schirbel, A., Wunderlich, G., Werner, R. A., Samnick, S., Kotzerke, J., Einsele, H., Buck, A. K., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.210997 · Cited by 107
Poty, S., Carter, L. M., Mandleywala, K., Membreno, R., Abdel-Atti, D., Ragupathi, A., Scholz, W. W., Zeglis, B. M., & Lewis, J. S. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1650 · Cited by 107
Ruigrok, E. A. M., van Vliet, N., Dalm, S. U., de Blois, E., van Gent, D. C., Haeck, J. C., de Ridder, C., Stuurman, D. C., Konijnenberg, M., van Weerden, W. M., et al. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-05057-6 · Cited by 104
Targeted Alpha Therapy: Current Clinical Applications
Liberal, F. D. C. G., O’Sullivan, J. M., McMahon, S. J., & Prise, K. M. (2020) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2020.3576 · Cited by 103
Rupp, N. J., Umbricht, C. A., Pizzuto, D. A., Lenggenhager, D. M., Töpfer, A., Müller, J., Muehlematter, U. J., Ferraro, D. A., Messerli, M., Morand, G. B., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.222307 · Cited by 97
Baum, R. P., Langbein, T., Singh, A., Shahinfar, M., Schuchardt, C., Volk, G. F., & Kulkarni, H. (2018) · Nuclear Medicine and Molecular Imaging · doi:10.1007/s13139-017-0508-3 · Cited by 94
Rathke, H. G., Kratochwil, C., Hohenberger, R., Giesel, F. L., Bruchertseifer, F., Flechsig, P., Morgenstern, A., Hein, M., Plinkert, P. K., Haberkorn, U., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4135-8 · Cited by 93
Self-citationBanerjee, S. R., Minn, I., Kumar, V., Josefsson, A., Lisok, A., Brummet, M. E., Chen, J., Kiess, A. P., Baidoo, K. E., Brayton, C. F., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.229393 · Cited by 93
Rosar, F., Hau, F., Bartholomä, M. D., Maus, S., Stemler, T., Linxweiler, J., Ezziddin, S., & Khreish, F. (2021) · Theranostics · doi:10.7150/thno.56211 · Cited by 93
Why Targeting PSMA Is a Game Changer in the Management of Prostate Cancer
Donin, N. M., & Reiter, R. E. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.191874 · Cited by 91
Kratochwil, C., Apostolidis, L., Rathke, H. G., Apostolidis, C., Bicu, F., Bruchertseifer, F., Choyke, P. L., Haberkorn, U., Giesel, F. L., & Morgenstern, A. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05474-1 · Cited by 95
Self-citationJuzeniene, A., Stenberg, V. Y., Bruland, Ø. S., & Larsen, R. H. (2021) · Cancers · doi:10.3390/cancers13040779 · Cited by 93
The Future of Radioligand Therapy: α, β, or Both?
Haberkorn, U., Giesel, F., Morgenstern, A., & Kratochwil, C. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.190124 · Cited by 88
Self-citationAlpha-PET for Prostate Cancer: Preclinical investigation using 149Tb-PSMA-617
Umbricht, C. A., Köster, U., Bernhardt, P., Gracheva, N., Johnston, K., Schibli, R., van der Meulen, N. P., & Müller, C. (2019) · Scientific Reports · doi:10.1038/s41598-019-54150-w · Cited by 88
Hooijman, E. L., Radchenko, V., Ling, S. W., Konijnenberg, M., Brabander, T., Koolen, S. L. W., & de Blois, E. (2024) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-024-00239-1 · Cited by 91
A Single Dose of 225Ac-RPS-074 Induces a Complete Tumor Response in an LNCaP Xenograft Model
Kelly, J. M., Amor‐Coarasa, A., Ponnala, S., Nikolopoulou, A., Williams, C. M., Thiele, N. A., Schlyer, D. J., Wilson, J. J., DiMagno, S. G., & Babich, J. W. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.219592 · Cited by 87
Clinical Advances and Perspectives in Targeted Radionuclide Therapy
Lepareur, N., Ramée, B., Mougin‐Degraef, M., & Bourgeois, M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15061733 · Cited by 86
van der Doelen, M. J., Mehra, N., van Oort, I. M., Looijen-Salamon, M. G., Janssen, M. J. R., Custers, J. A. E., Slootbeek, P. H. J., Kroeze, L. I., Bruchertseifer, F., Morgenstern, A., et al. (2021) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2020.12.002 · Cited by 85
Self-citationImplementing f-Block Metal Ions in Medicine: Tuning the Size Selectivity of Expanded Macrocycles
Thiele, N. A., Woods, J. J., & Wilson, J. J. (2019) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.9b01277 · Cited by 83
PSMA-Targeted Radionuclide Therapy and Salivary Gland Toxicity: Why Does It Matter?
Taïeb, D., Foletti, J. M., Bardiès, M., Rocchi, P., Hicks, R. J., & Haberkorn, U. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.207993 · Cited by 82
Self-citationSathekge, M., Bruchertseifer, F., Vorster, M., Lawal, I. O., Knoesen, O., Mahapane, J., Davis, C., Mdlophane, A., Maes, A., Mokoala, K., et al. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263618 · Cited by 81
Self-citationRecent advances in theranostics and challenges for the future
Turner, J. H. (2018) · British Journal of Radiology · doi:10.1259/bjr.20170893 · Cited by 79
Tagawa, S. T., Thomas, C., Sartor, A. O., Sun, M., Stangl-Kremser, J., Bissassar, M., Vallabhajosula, S., Castellanos, S. H., Nauseef, J. T., Sternberg, C. N., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.00573 · Cited by 78
Targeted and Nontargeted α-Particle Therapies
McDevitt, M. R., Sgouros, G., & Sofou, S. (2018) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-062117-120931 · Cited by 76
The Future of PSMA-Targeted Radionuclide Therapy: An Overview of Recent Preclinical Research
Ruigrok, E. A. M., van Weerden, W. M., Nonnekens, J., & de Jong, M. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11110560 · Cited by 75
Peters, S. M. B., Hofferber, R., Privé, B. M., de Bakker, M., Gotthardt, M., Janssen, M. J. R., de Lange, F., Muselaers, S., Mehra, N., Witjes, J. A., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05538-2 · Cited by 78
Dosimetry in radionuclide therapy: the clinical role of measuring radiation dose
Lawhn-Heath, C., Hope, T. A., Martinez, J., Fung, E. K., Shin, J., Seo, Y., & Flavell, R. R. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00657-4 · Cited by 77
The Future of Nuclear Medicine as an Independent Specialty
Czernin, J. G., Sonni, I., Razmaria, A. A., & Calais, J. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.220558 · Cited by 75
Radionuclide Therapy of Metastatic Prostate Cancer
Kratochwil, C., Haberkorn, U., & Giesel, F. L. (2019) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2019.02.003 · Cited by 76
Self-citationSatapathy, S., Sood, A. K., Das, C. K., & Mittal, B. R. (2021) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-021-00349-w · Cited by 73
Ma, J., Li, L., Liao, T., Gong, W., & Zhang, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.796657 · Cited by 77
An introduction to the clinical practice of theranostics in oncology
Turner, J. H. (2018) · British Journal of Radiology · doi:10.1259/bjr.20180440 · Cited by 73
van Boxtel, W., Lütje, S., Grunsven, I. C. H. V. E.-V., Verhaegh, G. W. C. T., Schalken, J. A., Jonker, M. A., Nagarajah, J., Gotthardt, M., & van Herpen, C. M. L. (2020) · Theranostics · doi:10.7150/thno.38501 · Cited by 72
225Ac-H4py4pa for Targeted Alpha Therapy
Li, L., Rousseau, J., Jaraquemada-Peláez, M. D. G., Wang, X., Robertson, A. K. H., Radchenko, V., Schaffer, P. C., Lin, K., Bénard, F., & Orvig, C. (2020) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.0c00171 · Cited by 72
Rousseau, É., Lau, J., Kuo, H., Zhang, Z., Merkens, H., Hundal-Jabal, N., Colpo, N., Lin, K., & Bénard, F. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.215350 · Cited by 69
Iravani, A., Violet, J., Azad, A., & Hofman, M. S. (2020) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-019-0174-x · Cited by 68
Shi, M., Jakobsson, V., Greifenstein, L., Khong, P.-L., Chen, X., Baum, R. P., & Zhang, J. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1034315 · Cited by 68
Targeted alpha therapy with bismuth‐213 and actinium‐225: Meeting future demand
Bruchertseifer, F., Kellerbauer, A., Malmbeck, R., & Morgenstern, A. (2019) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.3792 · Cited by 68
Self-citationAdvances in targeted alpha therapy for prostate cancer
Vincentis, G. D., Gerritsen, W. R., Gschwend, J. E., Hacker, M., Lewington, V. J., O’Sullivan, J. M., Oya, M., Pacilio, M., Parker, C. C., Shore, N. D., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz270 · Cited by 70
Implications of physics, chemistry and biology for dosimetry calculations using theranostic pairs
Miller, C., Rousseau, J., Ramogida, C. F., Celler, A. M., Rahmim, A., & Uribe, C. (2021) · Theranostics · doi:10.7150/thno.62851 · Cited by 67
Rowe, S. P., Gorin, M. A., & Pomper, M. G. (2019) · Annual Review of Medicine · doi:10.1146/annurev-med-062117-073027 · Cited by 66
Carrasquillo, J. A., Fine, B. M., Pandit-Taskar, N. D., Larson, S. M., Fleming, S. E., Fox, J. J., Cheal, S. M., O’Donoghue, J. A., Ruan, S., Ragupathi, G., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.222844 · Cited by 65
177Lu-labeled low-molecular-weight agents for PSMA-targeted radiopharmaceutical therapy
Banerjee, S. R., Kumar, V., Lisok, A., Chen, J., Minn, I., Brummet, M. E., Boinapally, S., Cole, M., Ngen, E. J., Wharram, B. L., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04434-0 · Cited by 64
PSMA Theranostics: Current Landscape and Future Outlook
Zhang, H., Koumna, S., Pouliot, F., Beauregard, J., & Kolinsky, M. P. (2021) · Cancers · doi:10.3390/cancers13164023 · Cited by 66
Lawal, I. O., Morgenstern, A., Vorster, M., Knoesen, O., Mahapane, J., Hlongwa, K., Maserumule, L. C., Ndlovu, H., Reed, J., Popoola, G. O., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05778-w · Cited by 64
Self-citationDevelopment of radiopharmaceuticals for targeted alpha therapy: Where do we stand?
Pallares, R. M., & Abergel, R. J. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1020188 · Cited by 64
Puttemans, J., Dekempeneer, Y., Eersels, J. L. H., Hanssens, H., Debie, P., Keyaerts, M., Windhorst, A. D., van der Aa, F., Lecocq, Q., Breckpot, K., et al. (2020) · Cancers · doi:10.3390/cancers12041017 · Cited by 64
Self-citation[177Lu]Lu-PSMA-617 Salivary Gland Uptake Characterized by Quantitative In Vitro Autoradiography
Tönnesmann, R., Meyer, P. T., Eder, M., & Baranski, A.-C. (2019) · Pharmaceuticals · doi:10.3390/ph12010018 · Cited by 63
Ling, S. W., de Blois, E., Hooijman, E. L., Veldt, A. A. M. V. D., & Brabander, T. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14102166 · Cited by 63
Kulkarni, H., Singh, A., Langbein, T., Schuchardt, C., Müeller, D., Zhang, J., Lehmann, C., & Baum, R. P. (2018) · British Journal of Radiology · doi:10.1259/bjr.20180308 · Cited by 61
Rosar, F., Krause, J., Bartholomä, M. D., Maus, S., Stemler, T., Hierlmeier, I., Linxweiler, J., Ezziddin, S., & Khreish, F. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13050722 · Cited by 61
Jeitner, T. M., Babich, J. W., & Kelly, J. M. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101450 · Cited by 62
Personalized Dosimetry in Targeted Radiation Therapy: A Look to Methods, Tools and Critical Aspects
Danieli, R., Milano, A., Gallo, S., Veronese, I., Lascialfari, A., Indovina, L., Botta, F., Ferrari, M. E., Cicchetti, A., Raspanti, D., et al. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12020205 · Cited by 60
Hooijman, E. L., Chalashkan, Y., Ling, S. W., Kahyargil, F. F., Segbers, M., Bruchertseifer, F., Morgenstern, A., Seimbille, Y., Koolen, S. L. W., Brabander, T., et al. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13050715 · Cited by 59
Self-citationNulent, T. J. W. K., van Es, R. J. J., Krijger, G. C., de Bree, R., Willems, S. M., & de Keizer, B. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3737-x · Cited by 59
The coordination properties and ionic radius of actinium: A 120-year-old enigma
Deblonde, G. J. ‐., Zavarin, M., & Kersting, A. B. (2021) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2021.214130 · Cited by 60
Metadata
- Authors
- Kratochwil, C., Bruchertseifer, F., Rathke, H., Bronzel, M., Apostolidis, C., Weichert, W., Haberkorn, U., Giesel, F. L., & Morgenstern, A.
- Affiliations
- University Hospital Heidelberg (DE)
- European Commission (BE)
- ABX-CRO Advanced Pharmaceutical Services (Germany) (DE)
- Pathologisches Institut (DE)
- German Cancer Research Center (DE)
- ORCID
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2017-04-13
- Volume
- 58
- Issue
- 10
- Pages
- 1624-1631
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- OpenAlex
- W2606187374
- Cited by
- 505
- References
- 31
- Citations by year
- 2026: 35 · 2025: 60 · 2024: 48 · 2023: 36 · 2022: 53 · 2021: 83 · 2020: 57 · 2019: 61 · 2018: 57 · 2017: 14
- FWCI
- 39.13
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Nuclear Medicine (publishedVersion)
- PubMed (publishedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Joint Research Centre (European Commission) (submittedVersion)
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- metastatic castration-resistant prostate cancer, dosimetry, 177Lu-PSMA-617, xerostomia, salvage therapy, PSA response, treatment toxicity
- MeSH terms
- Actinium, Aged, Alpha Particles, Dipeptides, Heterocyclic Compounds, 1-Ring, Humans, Male, Middle Aged, Neoplasm Metastasis, Radiometry, Radiotherapy Dosage, Prostate-Specific Antigen, Prostatic Neoplasms, Castration-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
